STAT+: Broad Institute, partners unveil new initiative to develop gene therapies for rare diseases

GSK has announced the discontinuation of its chronic cough treatment, marking the end of a long-running product line. The decision comes after years of regulatory scrutiny, clinical trial setbacks, and mounting pressure from competitors and healthcare providers. The company cited “strategic realignment” as the primary reason behind the move, though industry analysts suggest financial considerations played a role. The treatment, which had been marketed under multiple brand names over the past decade, was one of GSK's key offerings in respiratory care. The treatment, known internally as GSK-342, was initially approved in 2016 for the management of chronic cough associated with asthma or other chronic obstructive pulmonary disease (COPD). It was positioned as a non-opioid alternative to traditional cough suppressants, offering patients a safer option with fewer side effects. However, over time, the drug faced increasing challenges. Clinical trials revealed inconsistent efficacy rates, particularly among older adults, and some studies suggested potential interactions with other medications commonly prescribed to elderly patients. In 2021, the U.S. Food and Drug Administration (FDA) issued a warning letter to GSK regarding the safety profile of the medication, citing concerns over adverse effects such as dizziness and gastrointestinal distress. This prompted the company to conduct additional post-marketing studies, which further delayed the drug’s availability in certain markets. Meanwhile, rival pharmaceutical companies introduced newer, more effective treatments targeting similar conditions, eroding GSK’s market share. The decision to discontinue the treatment follows a broader trend in the pharmaceutical industry, where companies are increasingly shifting focus toward personalized medicine and gene therapy. In recent months, GSK has invested heavily in research related to genetic disorders and regenerative therapies, signaling a strategic pivot away from traditional small-molecule drugs. This shift aligns with growing interest in innovative treatments that address root causes rather than symptoms. Industry experts note that the discontinuation of GSK-342 reflects both the evolving landscape of respiratory care and the pressures of maintaining profitability in a highly competitive sector. While the drug will remain available for a limited period, patients currently using it will need to transition to alternative treatments. Healthcare professionals are advising caution, emphasizing the importance of evaluating each patient’s individual health profile before switching medications. Regulatory bodies are also monitoring the situation closely. The FDA has expressed concern over the abrupt withdrawal of a widely used medication and is considering whether to issue guidelines for managing such transitions. Some advocacy groups have called for greater transparency in how pharmaceutical companies decide to phase out products, arguing that patients should be fully informed of their options during such changes. Looking ahead, GSK plans to redirect resources toward its emerging gene therapy initiatives, including a partnership with Sonothera, a biotech firm specializing in ultrasound-based gene delivery systems. These projects represent a significant departure from the company’s earlier focus on conventional drug development. Analysts believe that while the discontinuation of GSK-342 is a setback for patients reliant on the medication, it also signals a bold step toward future innovation in therapeutic approaches.